Endo, Inc. (NDOI)
OTCMKTS · Delayed Price · Currency is USD
23.59
+0.49 (2.12%)
Inactive · Last trade price on Jul 31, 2025
Endo, Inc. Revenue
Endo, Inc. had revenue of $392.83M in the quarter ending March 31, 2025, a decrease of -6.36%. This brings the company's revenue in the last twelve months to $1.73B, down -9.52% year-over-year. In the year 2024, Endo, Inc. had annual revenue of $1.76B, down -12.50%.
Revenue (ttm)
1.73B
Revenue Growth
-9.52%
P/S Ratio
1.04
Revenue / Employee
556.31K
Employees
3,116
Market Cap
1.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.76B | -251.38M | -12.50% |
Dec 31, 2023 | 2.01B | -307.36M | -13.25% |
Dec 31, 2022 | 2.32B | -674.33M | -22.53% |
Dec 31, 2021 | 2.99B | 90.13M | 3.10% |
Dec 31, 2020 | 2.90B | -11.29M | -0.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEndo, Inc. News
- 8 days ago - Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader - PRNewsWire
- 16 days ago - Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting - PRNewsWire
- 19 days ago - Endo to Report Second Quarter 2025 Financial Results on August 6, 2025 - PRNewsWire
- 23 days ago - Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc. - PRNewsWire
- 25 days ago - Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025 - Business Wire
- 26 days ago - Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025 - Business Wire
- 26 days ago - OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 - GlobeNewsWire
- 6 weeks ago - Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025 - Business Wire